Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

India, South Africa gain from J&J generic deal, Patent Pool loses out (Spicy IP) (KEI)

Advair (Fluticasone propionate, Salmeterol) – Netherlands: GSK reverse on Dutch Advair patent and SPC (The SPC Blog) (The SPC Blog) (Kluwer Patent Blog)

Brazilian Attorney General of the Union restricts ANVISA’s role in pharmaceutical patent review (PatentlyBIOtech)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Technical symposium to address access to medicines, patent information and freedom to operate (WIPO)

Brazil: Brazilian Attorney General of the Union restricts ANVISA’s role in pharmaceutical patent review (PatentlyBIOtech)

India: Protection of Plant Varieties and Farmers’ Rights Authority appoints new Chairperson (Spicy IP)

Italy: Tribunale di Milano: Mere filing of application for marketing authorization of a generic drug does not constitute infringing activity: Eli Lilly v Ratiopharm (Kluwer Patent Blog)

Italy: Milan court considers admissibility of disclaimer in patent claim: Giellepi Chemicals S.R.L. v. Meda Pharma GmbH & Co. KG (EPLAW)

US: Another weeks, another missive on BPCIA exclusivity (FDA Law Blog)

US: The Preserve Access to Affordable Generics Act resurfaces early in the 112th Congress (FDA Law Blog)

US: Data or market exclusivity?: (Perhaps) only congress knows for sure (Patent Docs)

US: More on data exclusivity (Patent Docs)

US: BIO supports Patent Reform Act of 2011 (PatentlyBIOtech)

US: President Obama proposes, BIO agrees (Patent Docs)

US: Amicus briefs in AMP v USPTO: AARP (Patent Docs)

US: Orphan drug designations and applications took off in 2010 while orphan drug approvals tapered off (FDA Law Blog)

US: Dexcom wins major reexamination victories over Abbott (Reexamination Alert)

Products

Actonel (risedronate) – US: Warner Chilcott and Roche sue Teva over Actonel (The IP Factor)

Advair (Fluticasone propionate, Salmeterol) – Netherlands: GSK reverse on Dutch Advair patent and SPC (The SPC Blog) (The SPC Blog) (Kluwer Patent Blog)

Caduet (Amlodipine , Atorvastatin) – US: Mylan settles with Pfizer in Lipitor and Caduet patent suits (Patent Docs)

Fabrazyme (Alpha-galactosidase) – US patients petition FDA to regulate Genzyme export of Fabrazyme (Patent Docs)

Gemzar (Gemcitabine) – Teva and APP announce launch of generic Gemzar pursuant to agreement (SmartBrief)

Gemzar (Gemcitabine) – US: Eli Lilly petitions for certiorari in Sun v Eli Lilly (Holman’s Biotech IP Blog)

Lipitor (Atorvastatin) – US: Mylan settles with Pfizer in Lipitor and Caduet patent suits (Patent Docs)

Memantine – Belgium: Brussels Commercial Court hands down judgment in Synthon v Merz (The SPC Blog) (The SPC Blog)

Rilpivirine – India, South Africa gain from J&J generic deal, Patent Pool loses out (Spicy IP) (KEI)

Sular (Nisoldipine) – US: Mylan receives approval for first to file generic Sular extended-release tablets (SmartBrief)

Tarka (Trandolapril, Verapamil) – US: Jury awards Abbott $16M in Tarka patent suit against Glenmark (Patent Docs)

Uroxatral (Alfuzosin) – US: Sanofi-Aventis Uroxatral patent found valid and infringed by Apotex (Patent Docs)